THC-based antiemetics are FDA-approved for chemotherapy-induced nausea — and CBDA shows 1000x greater potency than CBD for anticipatory nausea.
Chemotherapy-induced nausea and vomiting (CINV) affects 70–80% of cancer patients receiving chemotherapy and is one of the most feared side effects of cancer treatment. Dronabinol (synthetic THC) and nabilone are FDA-approved antiemetics for CINV. CBDA has emerged as a remarkably potent antiemetic for anticipatory nausea — a conditioned response that does not respond to conventional antiemetics.
1.5 million cancer patients annually
Americans Affected
CINV affects 70–80% of chemotherapy patients
Prevalence
2
Key Studies
3
Cannabinoids Reviewed
THC activates CB1 receptors in the dorsal vagal complex and nucleus tractus solitarius — the brain's vomiting center — suppressing the emetic reflex. Dronabinol (synthetic THC) is FDA-approved for CINV refractory to conventional antiemetics. CBDA reduces anticipatory nausea at doses 1000x lower than CBD via 5-HT1A agonism.
CB1 receptors in the dorsal vagal complex (DVC) and nucleus tractus solitarius (NTS) — the brainstem's vomiting control centers — suppress the emetic reflex when activated by THC. This is the mechanism of dronabinol and nabilone, both FDA-approved for CINV.
Anticipatory nausea is a conditioned response that does not respond to 5-HT3 antagonists (ondansetron) or NK1 antagonists — the standard CINV medications. CBDA reduces anticipatory nausea via 5-HT1A agonism at doses 1000x lower than CBD, making it a highly potent candidate for this unmet clinical need.
THC activates CB1 receptors in the hypothalamus, stimulating appetite and reducing nausea-associated anorexia. This dual antiemetic/appetite-stimulating effect is particularly valuable in cancer patients at risk of cachexia.
Dronabinol (synthetic THC) and nabilone are FDA-approved for CINV refractory to conventional antiemetics. Also stimulates appetite.
Reduces anticipatory nausea at 1000x lower doses than CBD in preclinical models via 5-HT1A. Addresses a major unmet clinical need. Human trials pending.
CBD has antiemetic activity via 5-HT1A but is less potent than CBDA for anticipatory nausea. May reduce anxiety component of nausea.
Dronabinol vs. Prochlorperazine for CINV
Dronabinol superior to prochlorperazine for CINV control (25% vs. 15% complete control). Also improved appetite.
CBDA Reduces Anticipatory Nausea in Rat Model
CBDA reduced anticipatory nausea at doses 1000x lower than CBD via 5-HT1A mechanism.
Dosing information is for educational purposes only. Always start with the lowest effective dose and consult a healthcare provider before use.
Start Dose
2.5mg twice daily
Target Dose
5–10mg before chemotherapy
Timing
1–3 hours before chemotherapy
FDA-approved. Prescription only. Start low to assess psychoactive tolerance.
Start Dose
1–2 puffs
Target Dose
Titrate to effect
Timing
At onset of nausea
Fastest onset. Useful for breakthrough nausea. Use high-THC, low-CBD strains.